BRAF and melanoma: Treatments inhibiting the enzymatic activity of mutated BRAF protein, a serine‐threonine protein kinase, in patients with advanced or metastatic melanoma (MM) became available in 2010 and have demonstrated improved progression‐free survival (PFS) and overall survival (OS) for patients with BRAF‐mutated melanoma 1, 2.